Furthermore, given the SDHB mutational status of 4 responders and the ability of another imipridone compound with similar profile to downregulate SDH-A/B in other cancer preclinical models, it could be interesting to evaluate a possible enhanced efficacy of ONC201in SDH deficient tumors. The gene discussed is SDHB; the disease is cancer.